Mustafa Emiroglu, Kenan Cetin, Kerim Bora Yilmaz, Mehmet Velidedeoglu, Sadullah Girgin, Alper Akcan, Ozgur Aytac, Murat Akın, Hande Koksal, Neslihan Cabioglu, Nuh Zafer Canturk, Bahadır Gulluoglu
{"title":"特发性肉芽肿性乳腺炎:基于土耳其临床分类的治疗和随访方法的共识报告。","authors":"Mustafa Emiroglu, Kenan Cetin, Kerim Bora Yilmaz, Mehmet Velidedeoglu, Sadullah Girgin, Alper Akcan, Ozgur Aytac, Murat Akın, Hande Koksal, Neslihan Cabioglu, Nuh Zafer Canturk, Bahadır Gulluoglu","doi":"10.1159/000544967","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The second consensus study on idiopathic granulomatous mastitis (IGM) aimed to establish treatment options based on the clinical classification proposed in the first consensus, standardize criteria for treatment discontinuation, and develop follow-up protocols.</p><p><strong>Method: </strong>A structured methodology, identical to the first consensus study, was employed. An 11-member working group of breast surgeons experienced in IGM from various clinics across the country was formed. The modified Delphi method was used, with a consensus threshold of 80% agreement.</p><p><strong>Results: </strong>Three voting rounds were conducted to develop the IGM treatment algorithm. In Round 1, observation was established as the first-line option for Type 1 disease (81%) and pregnancy/lactation cases (85%). Round 2 achieved consensus on systemic steroids (SS) as the first-line treatment for Type 3 cases (84%), combination therapies for resistant cases (82%), and reclassification of recurrent cases to guide treatment planning (94%). In Round 3, consensus was reached on the use of immunosuppressive therapy (IMT) for cases where steroids are contraindicated in Type 3 (81%), the use of IMT for resistant cases (93%), avoiding surgery as the first-line option for Type 1 cases (81%), and requiring complete clinical and radiological response before discontinuing treatment (81%). However, no consensus was reached on the first-line treatment for Type 2 disease.</p><p><strong>Conclusion: </strong>This consensus study successfully developed a treatment algorithm for IGM, prioritizing observation for Type 1 disease and cases involving pregnancy or lactation, and recommending systemic steroids (SS) and immunosuppressive therapies for Type 3 cases. The findings underscore the critical importance of achieving complete clinical and radiological remission before discontinuing treatment. However, the lack of consensus on the treatment of Type 2 disease highlights the need for further research into this challenging subtype.</p>","PeriodicalId":9310,"journal":{"name":"Breast Care","volume":"20 4","pages":"248-255"},"PeriodicalIF":2.1000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377798/pdf/","citationCount":"0","resultStr":"{\"title\":\"Idiopathic Granulomatous Mastitis: A Consensus Report on Treatment and Follow-Up Approaches Based on the Turkish Clinical Classification.\",\"authors\":\"Mustafa Emiroglu, Kenan Cetin, Kerim Bora Yilmaz, Mehmet Velidedeoglu, Sadullah Girgin, Alper Akcan, Ozgur Aytac, Murat Akın, Hande Koksal, Neslihan Cabioglu, Nuh Zafer Canturk, Bahadır Gulluoglu\",\"doi\":\"10.1159/000544967\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The second consensus study on idiopathic granulomatous mastitis (IGM) aimed to establish treatment options based on the clinical classification proposed in the first consensus, standardize criteria for treatment discontinuation, and develop follow-up protocols.</p><p><strong>Method: </strong>A structured methodology, identical to the first consensus study, was employed. An 11-member working group of breast surgeons experienced in IGM from various clinics across the country was formed. The modified Delphi method was used, with a consensus threshold of 80% agreement.</p><p><strong>Results: </strong>Three voting rounds were conducted to develop the IGM treatment algorithm. In Round 1, observation was established as the first-line option for Type 1 disease (81%) and pregnancy/lactation cases (85%). Round 2 achieved consensus on systemic steroids (SS) as the first-line treatment for Type 3 cases (84%), combination therapies for resistant cases (82%), and reclassification of recurrent cases to guide treatment planning (94%). In Round 3, consensus was reached on the use of immunosuppressive therapy (IMT) for cases where steroids are contraindicated in Type 3 (81%), the use of IMT for resistant cases (93%), avoiding surgery as the first-line option for Type 1 cases (81%), and requiring complete clinical and radiological response before discontinuing treatment (81%). However, no consensus was reached on the first-line treatment for Type 2 disease.</p><p><strong>Conclusion: </strong>This consensus study successfully developed a treatment algorithm for IGM, prioritizing observation for Type 1 disease and cases involving pregnancy or lactation, and recommending systemic steroids (SS) and immunosuppressive therapies for Type 3 cases. The findings underscore the critical importance of achieving complete clinical and radiological remission before discontinuing treatment. However, the lack of consensus on the treatment of Type 2 disease highlights the need for further research into this challenging subtype.</p>\",\"PeriodicalId\":9310,\"journal\":{\"name\":\"Breast Care\",\"volume\":\"20 4\",\"pages\":\"248-255\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377798/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast Care\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000544967\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000544967","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
Idiopathic Granulomatous Mastitis: A Consensus Report on Treatment and Follow-Up Approaches Based on the Turkish Clinical Classification.
Objective: The second consensus study on idiopathic granulomatous mastitis (IGM) aimed to establish treatment options based on the clinical classification proposed in the first consensus, standardize criteria for treatment discontinuation, and develop follow-up protocols.
Method: A structured methodology, identical to the first consensus study, was employed. An 11-member working group of breast surgeons experienced in IGM from various clinics across the country was formed. The modified Delphi method was used, with a consensus threshold of 80% agreement.
Results: Three voting rounds were conducted to develop the IGM treatment algorithm. In Round 1, observation was established as the first-line option for Type 1 disease (81%) and pregnancy/lactation cases (85%). Round 2 achieved consensus on systemic steroids (SS) as the first-line treatment for Type 3 cases (84%), combination therapies for resistant cases (82%), and reclassification of recurrent cases to guide treatment planning (94%). In Round 3, consensus was reached on the use of immunosuppressive therapy (IMT) for cases where steroids are contraindicated in Type 3 (81%), the use of IMT for resistant cases (93%), avoiding surgery as the first-line option for Type 1 cases (81%), and requiring complete clinical and radiological response before discontinuing treatment (81%). However, no consensus was reached on the first-line treatment for Type 2 disease.
Conclusion: This consensus study successfully developed a treatment algorithm for IGM, prioritizing observation for Type 1 disease and cases involving pregnancy or lactation, and recommending systemic steroids (SS) and immunosuppressive therapies for Type 3 cases. The findings underscore the critical importance of achieving complete clinical and radiological remission before discontinuing treatment. However, the lack of consensus on the treatment of Type 2 disease highlights the need for further research into this challenging subtype.
期刊介绍:
''Breast Care'' is a peer-reviewed scientific journal that covers all aspects of breast biology. Due to its interdisciplinary perspective, it encompasses articles on basic research, prevention, diagnosis, and treatment of malignant diseases of the breast. In addition to presenting current developments in clinical research, the scope of clinical practice is broadened by including articles on relevant legal, financial and economic issues.